Oltipraz in the Prevention of Lung Cancer in People Who Smoke

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00006457
Recruitment Status : Completed
First Posted : May 30, 2003
Last Update Posted : June 11, 2012
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Northwestern University

Brief Summary:

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer.

PURPOSE: Randomized phase I trial to study the effectiveness of oltipraz in preventing lung cancer in people who smoke.

Condition or disease Intervention/treatment Phase
Lung Cancer Drug: oltipraz Phase 1

Detailed Description:


  • Determine the effect of oltipraz on the level of BP-7,8-diol-9,10-epoxide (BPDE) DNA adducts in the lung lining cells (macrophages and bronchial epithelial cells) of smokers.
  • Determine the tolerability and toxicity of this treatment regimen in these patients.
  • Determine the effect of this treatment regimen on the level of macromolecule adducts in the blood (e.g., BPDE DNA, BPDE hemoglobin, and 8-hydroxy-deoxyguanine), oral lining cells (BPDE DNA), bladder lining cells (4-aminobiphenyl DNA), and lung macrophages (8-hydroxy-deoxyguanine) in these patients.
  • Determine the effect of this treatment regimen on the change (decrease) in activation of NNK as measured by change (increase) in urinary NNAL plus NNAL glucuronide in these patients.
  • Determine the effect of this treatment regimen on the oxidative state, glutathione-S-transferase activity, and superoxide dismutase 3 and phase II enzymes in the lungs and blood of these patients.
  • Compare the changes in oxidative state and phase II enzymes with changes in adduct levels in the lungs and blood of these patients.
  • Determine the correlation between oltipraz-induced changes in phase II enzymes and adduct formation with genotypic variation in glutathione-S-transferase isozymes in these patients.
  • Compare the response to this treatment regimen in terms of oxidative state, phase II enzymes, and adduct formation in the lungs vs the blood in these patients.

OUTLINE: This is a randomized, double-blind, multicenter study. Patients are stratified according to participating center. Patients are randomized to one of three treatment arms.

  • Arm I: Patients receive an oral placebo weekly.
  • Arm II: Patients receive low-dose oral oltipraz weekly.
  • Arm III: Patients receive high-dose oral oltipraz weekly. Treatment continues for 12 weeks in the absence of unacceptable toxicity.

Patients are followed at 4 weeks.

PROJECTED ACCRUAL: A total of 66 patients (22 per treatment arm) will be accrued for this study within 21 months.

Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Masking: Double
Primary Purpose: Prevention
Official Title: Clinical Phase I Multiple-Dose Safety Research Study of Oltipraz in Smokers
Study Start Date : August 2000
Actual Primary Completion Date : April 2004
Actual Study Completion Date : April 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Current cigarette smokers

    • At least 20 cigarettes a day
    • No variation of more than 10 in the number of cigarettes smoked per day within the past 3 months
    • At least 10 years of smoking any amount
    • Failed to stop smoking after at least one attempt to quit within the last 3 years
  • Prior stage I non-small cell lung cancer allowed if surgically resected with at least a lobectomy
  • No concurrent evidence of lung cancer
  • Willing to undergo 2 bronchoscopies



  • 18 and over

Performance status:

  • ECOG 0

Life expectancy:

  • Not specified


  • CBC normal
  • Hemostasis normal


  • PT and PTT normal


  • Blood chemistries normal
  • Nonfasting glucose no greater than 200 mg/dL
  • No active renal disease
  • No urinary tract infection by urinalysis (trace protein allowed)


  • EKG normal
  • No coronary artery disease requiring continuous medication


  • Chest radiograph normal (postsurgical changes allowed)
  • No acute or significant chronic abnormality
  • FEV1 greater than 1.8 L or 75% predicted
  • No chronic obstructive pulmonary disease requiring continuous medication


  • No known hypersensitivity or prior adverse reaction to oltipraz
  • No inmates or prisoners
  • No medical or psychological condition that would preclude study (e.g., acute psychosis)
  • No prior malignancy except nonmelanomatous skin cancer, cervical dysplasia, or curatively treated stage I or II cancer of the head and neck
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 6 months after study


Biologic therapy:

  • Not specified


  • At least 3 months since prior potential chemoprevention agent (e.g., oltipraz, retinoids, or acetylcysteine)

Endocrine therapy:

  • Not specified


  • Not specified


  • See Disease Characteristics

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00006457

United States, Illinois
Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois, United States, 60611-3013
United States, North Carolina
Duke Comprehensive Cancer Center
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
Northwestern University
National Cancer Institute (NCI)
Study Chair: Raymond C. Bergan, MD Robert H. Lurie Cancer Center

Responsible Party: Northwestern University Identifier: NCT00006457     History of Changes
Other Study ID Numbers: NCI 00L1
First Posted: May 30, 2003    Key Record Dates
Last Update Posted: June 11, 2012
Last Verified: June 2012

Keywords provided by Northwestern University:
non-small cell lung cancer
small cell lung cancer

Additional relevant MeSH terms:
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Antiviral Agents
Anti-Infective Agents
Antiplatyhelmintic Agents
Antiparasitic Agents
Anticarcinogenic Agents
Protective Agents
Physiological Effects of Drugs
Antineoplastic Agents
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents